Comparative Pharmacology
Head-to-head clinical analysis: MAGNESIUM SULFATE versus POTASSIUM CHLORIDE 0 3 IN DEXTROSE 5 AND SODIUM CHLORIDE 0 33 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAGNESIUM SULFATE versus POTASSIUM CHLORIDE 0 3 IN DEXTROSE 5 AND SODIUM CHLORIDE 0 33 IN PLASTIC CONTAINER.
MAGNESIUM SULFATE vs POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Magnesium sulfate acts as a physiological calcium channel blocker. It inhibits calcium influx into presynaptic nerve terminals, reducing acetylcholine release at the neuromuscular junction and decreasing muscle contraction. It also antagonizes NMDA receptors and stabilizes neuronal membranes.
Potassium chloride provides potassium ions, essential for maintenance of intracellular tonicity, nerve impulse conduction, muscle contraction, and acid-base balance. Dextrose 5% provides caloric support and may help prevent ketosis. Sodium chloride 0.33% provides sodium and chloride ions to maintain electrolyte balance and osmotic pressure.
IV: Loading dose 4-6 g over 20-30 minutes, followed by maintenance infusion 1-2 g/hour for seizure prophylaxis in severe preeclampsia/eclampsia. IM: 4-8 g deep IM initially, then 4 g every 4 hours as needed.
Intravenous infusion at a rate determined by serum potassium levels; typical maintenance: 10-20 mEq potassium per hour, not to exceed 40 mEq/hour; maximum daily dose: 200 mEq. Adjust based on patient's electrolyte status and renal function.
None Documented
None Documented
Clinical Note
moderateMagnesium sulfate + Gatifloxacin
"The serum concentration of Gatifloxacin can be decreased when it is combined with Magnesium sulfate."
Clinical Note
moderateMagnesium sulfate + Rosoxacin
"The serum concentration of Rosoxacin can be decreased when it is combined with Magnesium sulfate."
Clinical Note
moderateMagnesium sulfate + Levofloxacin
"The serum concentration of Levofloxacin can be decreased when it is combined with Magnesium sulfate."
Clinical Note
moderateTerminal elimination half-life approximately 4-6 hours in patients with normal renal function; prolonged to 12-24 hours or more in renal impairment, necessitating dose adjustment
The terminal half-life is approximately 2-4 hours in patients with normal renal function. Clinical context: half-life extends significantly in renal impairment (e.g., up to 24-48 hours in oliguric patients) and is dependent on total body potassium stores and redistribution kinetics.
Primarily renal (90-95% as unchanged drug); minor biliary/fecal (<5%)
Potassium is primarily excreted renally (90%) with minor fecal (10%) losses. Renal elimination involves glomerular filtration and distal tubular secretion; 80-90% is reabsorbed, with excretion adjusted by aldosterone. In dextrose/saline, potassium excretion parallels sodium and water handling.
Category C
Category A/B
Electrolyte
Electrolyte
Magnesium sulfate + Trovafloxacin
"The serum concentration of Trovafloxacin can be decreased when it is combined with Magnesium sulfate."